Background: Migraine headaches are a severe and disabling neurovascular disorder affecting nearly 20% of adults in the United States¹. Calcitonin Gene Related Peptide (CGRP) monoclonal antibodies (mAB) is a new class of anti-migraine drugs that represent the first targeted therapy for the prevention of migraine.